Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| PUMA BIOTECHNOLOGY, Inc. (NASDAQ: PBYI) | Delayed: 11.29 +0.39 (3.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.90 | 52 Week High | $82.81 | |||
| Open | $10.93 | 52 Week Low | $19.74 | |||
| Day High | $11.33 | P/E | N/A | |||
| Day Low | $10.92 | EPS | $-2.16 | |||
| Volume | 79,865 | |||||
